Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action

Molecular Pharmacology

Volumn 87, Issue 2, 2015, Pages 251-262

  Bradley, M E ^a   Dombrecht, B ^b   Manini, J ^a   Willis, J ^a   Vlerick, D ^b   De Taeye, S ^b   Van Den Heede, K ^b   Roobrouck, A ^b   Grot, E ^a   Kent, T C ^a   Laeremans, T ^c   Steffensen, S ^b   Van Heeke, G ^a   Brown, Z ^a   Charlton, S J ^a   Cromie, K D ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b ABLYNX NV   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; NANOBODY;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATION; NEUTROPHIL; NONHUMAN; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTIODACTYLA; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HAMSTER; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CAMELIDS, NEW WORLD; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION; SINGLE-DOMAIN ANTIBODIES;

EID: 84920583576     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.094821     Document Type: Article

References (31)

1. Behdani M, Zeinali S, Khanahmad H, Karimipour M, Asadzadeh N, Azadmanesh K, Khabiri A, Schoonooghe S, Habibi Anbouhi M, and Hassanzadeh-Ghassabeh G et al. (2012) Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol Immunol 50: 35-41.
2. Bradford MM (1976) A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
3. Bradley ME, Bond ME, Manini J, Brown Z, and Charlton SJ (2009) SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Br J Pharmacol 158: 328-338.
4. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, and Fine JS (2009) CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 121: 55-68.
5. Damian M, Martin A, Mesnier D, Pin JP, and Banères JL (2006) Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J 25: 5693-5702.
6. Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, and Deno G et al. (2007) Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 322: 477-485.
7. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, and Hamers R (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
8. Hertzer KM, Donald GW, and Hines OJ (2013) CXCR2: a target for pancreatic cancer treatment? Expert Opin Ther Targets 17: 667-680.
9. Hoare SR (2007) Allosteric modulators of class B G-protein-coupled receptors. Curr Neuropharmacol 5: 168-179.
10. Horcher M, Rot A, Aschauer H, and Besemer J (1998) IL-8 derivatives with a reduced potential to form homodimers are fully active in vitro and in vivo. Cytokine 10: 1-12.
11. Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, and Vandevelde W et al. (2010) CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci USA 107: 20565-20570.
12. Katancik JA, Sharma A, and de Nardin E (2000) Interleukin 8, neutrophil-activating peptide-2 and GRO-alpha bind to and elicit cell activation via specific and different amino acid residues of CXCR2. Cytokine 12: 1480-1488.
13. Kolkman JA and Law DA (2010) Nanobodies - from llamas to therapeutic proteins. Drug Discov Today Technol 7: e136-e146 DOI: 10.1016/j.ddtec.2010.03.002.
14. Maussang D, Mujic-Delic A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, and Gonzalez-Pajuelo M et al. (2013) Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem 288: 29562-29572.
15. Muyldermans S (2001) Single domain camel antibodies: current status. J Biotechnol 74: 277-302.
16. Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, and Golmakani N (2004) Production of a novel camel single-domain antibody specific for the type III mutant EGFR. Tumour Biol 25: 296-305.
17. Paes C, Ingalls J, Kampani K, Sulli C, Kakkar E, Murray M, Kotelnikov V, Greene TA, Rucker JB, and Doranz BJ (2009) Atomic-level mapping of antibody epitopes on a GPCR. J Am Chem Soc 131: 6952-6954.
18. Ravindran A, Sawant KV, Sarmiento J, Navarro J, and Rajarathnam K (2013) Chemokine CXCL1 dimer is a potent agonist for the CXCR2 receptor. J Biol Chem 288: 12244-12252.
19. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, and van Bergen Henegouwen PM (2007) Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 56: 303-317.
20. Salchow K, Bond ME, Evans SC, Press NJ, Charlton SJ, Hunt PA, and Bradley ME (2010) A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol 159: 1429-1439.
21. Schall TJ and Proudfoot AEI (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 11: 355-363.
22. Sharma B, Nawandar DM, Nannuru KC, Varney ML, and Singh RK (2013) Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis. Mol Cancer Ther 12: 799-808.
23. Siontorou CG (2013) Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomedicine 8: 4215-4227.
24. Slørdahl TS, Denayer T, Moen SH, Standal T, Børset M, Ververken C, and Rø TB (2013) Anti-c-MET nanobody - a new potential drug in multiple myeloma treatment. Eur J Haematol 91: 399-410.
25. Stadtmann A and Zarbock A (2012) CXCR2: from bench to bedside. Front Immunol 3: 263-275.
26. Trettel F, Di Bartolomeo S, Lauro C, Catalano M, Ciotti MT, and Limatola C (2003) Ligand-independent CXCR2 dimerization. J Biol Chem 278: 40980-40988.
27. Unciti-Broceta JD, Del Castillo T, Soriano M, Magez S, and Garcia-Salcedo JA (2013) Novel therapy based on camelid nanobodies. Ther Deliv 4: 1321-1336.
28. Van Bockstaele F, Holz JB, and Revets H (2009) The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 10: 1212-1224.
29. Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, Muyldermans S, Lahoutte T, and Caveliers V (2011) Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 25: 2433-2446.
30. Vauquelin G and Charlton SJ (2013) Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol 168: 1771-1785.
31. Vauquelin G, Hall DA, and Charlton SJ (2015) "Partial" competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models. Br J Pharmacol, in press DOI: 10.1111/bph.13053.